This article is part of the PlexusDx Education Hub evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables behind every metabolic decision
Its very small less than one percent but its still worth noting
Post-marketing surveillance and case reports have documented isolated instances of patients reporting muscle pain, cramping, or weakness while taking GLP-1 medications, though establishing a direct causal relationship remains challenging
For young people, surgery is going to be even safer than average, and the effects of that they'll be able to experience for a longer time
Most patients notice reduced appetite within the first two to four weeks, with measurable weight loss appearing by weeks eight to twelve
This raises questions about cost-effectiveness and access, but if priced reasonably or if generics eventually become available, we may see a broad shift where anti-obesity pharmacotherapy (especially GLP-1/GIP-based) is as commonplace as antihypertensive or lipid-lowering therapy